完整分析組包括LHQW膠囊組410名患者和安慰劑組405名患者。在完整分析組中,LHQW顯著縮短了主要終點的時間(4.0 vs. 6.7天,風險比:1.63,95%置信區間:1.39-1.90)。LHQW膠囊縮短了持續臨床改善或鼻塞、流感症狀(2.8 vs. 3.7天)、喉嚨痛(2.0 vs. 2.6天)、咳嗽(3.2 vs. 4.9天)、發熱感(1.0 vs. 1.3天)、低能量或疲勞感(1.3 vs. 1.9天)以及肌肉疼痛(1.5 vs. 2.0天)的中位時間。在兩組之間,持續臨床改善或呼吸急促、頭痛以及寒戰或發冷的中位時間沒有顯著差異。兩組的安全性相當,未報告嚴重不良事件。
結論
LHQW膠囊可中輕度症狀緩解,促進輕度至中度COVID-19的恢複,並且耐受性良好。
實驗分組沒有按照中醫理論
受試者入選的條件是18-70歲之間,輕中度新冠患者,核酸或抗原檢測陽性,至少有三個症狀:
Briefly, eligible patients were aged 18-70 years, had mild-to-moderate COVID-19 (according World Health Organization), tested positive to either rapid antigen test (RAT) or nucleic acid amplification test (NAAT), had an interval between symptom onset and screening of within 4 days, and had at least three major symptoms (stuffy or runny nose, sore throat, cough, shortness of breath, low energy or tiredness, myalgia, headache, chills or shivering, feeling hot or feverish) occurring within 12 hours prior to screening.
Both groups received standard-of-care consisting of antipyretics, analgesic drugs, nutrition supplementation and fluid replacement. Acetaminophen, the non-steroidal anti-inflammatory drug, could be applied for ameliorating fever if the temperature reached 38.5 degrees or higher.
給了什麽解熱鎮痛的藥物,語焉不詳。補充材料有一段說明[6]:
Symptomatic treatment such as antipyretic analgesia, adequate nutrition and appropriate rehydration in patients with mild COVID-19 were allowed according to the study protocol. Antipyretic and analgesic acetaminophen could be given as symptomatic treatment when the body temperature exceeded 38.5°C.